GlassScriptPhysician profile
Morgan Gustin
NPI 1447876511
$6,194.25
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,882 · 2022: $2,341 · 2023: $880 · 2024: $91.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $986.68 | 2021-2023 | Rexulti, Abilify Maintena |
| Abbvie INC. | $670.23 | 2021-2024 | |
| Alkermes, INC. | $630.55 | 2021-2023 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $377.76 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $367.22 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $314.54 | 2021-2023 | Spravato |
| Ironshore Pharmaceuticals INC. | $314.35 | 2021-2023 | Jornay Pm |
| Neos Therapeutics, LP | $303.65 | 2021-2023 | Adzenys Xr-Odt |
| Corium, LLC | $259.13 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $257.63 | 2021-2022 | |
| Lundbeck LLC | $222.90 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $209.47 | 2022 | |
| Tris Pharma INC | $195.00 | 2021-2023 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $144.37 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $126.89 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $121.32 | 2021 | |
| Eisai INC. | $118.20 | 2021-2022 | |
| Axsome Therapeutics, INC. | $113.85 | 2022-2023 | Auvelity |
| Bausch Health US, LLC | $113.39 | 2021-2022 | |
| Adlon Therapeutics L.P. | $71.84 | 2021 | |
| Merck Sharp & Dohme LLC | $50.26 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $48.24 | 2021 | |
| Alfasigma USA, INC. | $34.96 | 2021 | |
| Vanda Pharmaceuticals INC. | $31.85 | 2021-2022 | |
| Noven Therapeutics, LLC | $30.92 | 2023 | Xelstrym |
| Owp Pharmaceuticals, INC. | $25.55 | 2022 | |
| Livanova USA, INC. | $23.04 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.88 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.58 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Gustin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.